萨瓦拉制药

关于 Savara

Savara, Inc. is a clinical-stage 制药 company, which 从事 the 开发 and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program 包括 molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being 开发 for the treatment of autoimmune pulmonary alveolar proteinosis. The company was 成立 in December 1995 and is 总部位于 in Langhorne, PA.

成立时间

1995

首席执行官

Mr. Matthew Pauls, J.D.,M.B.A.

员工人数

70

总部地址

Langhorne, Pennsylvania, United States of America

财年结束日

12-31

官方网站

savarapharma.com

公司概况

交易所

US

股票代码

SVRA

市值排名

#3247

市值

914.30M

流通市值

360.75M

总股数

205.46M

流通股数

81.07M

行业与主题板块

浏览全部行业与主题板块